期刊文献+

格列美脲与胰岛素治疗2型糖尿病81例临床分析

Glimepiride and Insulin Treatment in Type 2 Diabetes
下载PDF
导出
摘要 目的:探讨应用格列美脲(万苏平)与胰岛素治疗2型糖尿病(T2DM)的血脂、血红蛋白、血糖临床疗效及安全性。方法:对81例T2DM患者,采用格列美脲与胰岛素治疗2型糖尿病进行临床治疗,观察格列美脲与胰岛素治疗糖尿病患者后其血糖、糖化血红蛋白(HbA1c)及血脂等指标的变化。结果:格列美脲与胰岛素治疗2糖尿病效果显著。结论:格列美脲与胰岛素可作为2型糖尿病患者的备选降糖药物。 Objective:The discussion using the Glimepiride(Wan Suping) in 2 diabetes with the insulin(T2DM) the blood fats,the hemoglobin,the blood sugar clinical curative effect and the security.Method:To 81 example T2DM patient,uses the Geleg beautiful urea and the insulin treats 2 diabetes to carry on the clinical care,after observing the Geleg beautiful urea and the insulin treat the diabetic,its blood sugar,saccharification hemoglobin(HbA1c) and target and so on blood fats changes.Results:The Geleg beautiful urea and the insulin treat 2 diabetes effects to be remarkable.Conclusion:The Geleg beautiful urea and the insulin may take 2 diabetics alternative to fall the sugar medicine.
作者 袁尚恒
出处 《华西医学》 CAS 2008年第4期757-758,共2页 West China Medical Journal
关键词 格列美脲 2型糖尿病 胰岛素 glimepiride insulin in type 2 diabetes
  • 相关文献

参考文献6

  • 1K Bar,do, Y Yamda. Glimepiride (Anraryl) : a review of its pharmacological and clinical profile [J]. Nippon Yakurigaku Zasshi, 2001, 118: 59-67.
  • 2Worhl health organization. Definition, diagnosis and classification of diabtes mellitus and its complication[M]. WHO/NCD/NCS, 1999: 31-32.
  • 3Butler AE,Janson J,Bonner-Weir S,et al.β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes[J].Diabetes,2003,52:102-110.
  • 4邓尚平.磺脲类药物治疗2型糖尿病的几个问题[J].中华糖尿病杂志(1006-6187),2005,13(3):236-238. 被引量:19
  • 5颜云湘.第3代磺脲类抗糖尿病药——格列美脲片[J].中国临床药学杂志,2006,15(5):334-335. 被引量:48
  • 6杨晶雪 刘国良.葡萄糖毒性作用在2型糖尿病中的表达及处理的研究[J].实用糖尿病杂志,1998,6(1):36-37.

二级参考文献22

  • 1陈月,邹大进,曲伸,刘岩.格列美脲治疗2型糖尿病病人的降糖作用及其安全性评价[J].药学服务与研究,2004,4(3):281-282. 被引量:4
  • 2滕彩华,刘翠英,陈健仁,等.糖尿病的口服降糖药物治疗.见:邓尚平主编.临床糖尿病学.第1版.成都:四川科学技术出版社,2000.109-115.
  • 3Inagaki N, Gonoi T, Clement JP 4th, et al. Reconstitution of KATP: An inward rectifier- subunit plus the sulfonylurea receptor. Science,1995,270:1166-1170.
  • 4Dorschner H, Brakardin E, Uhde I, et al. Stoichiometry of sulfonylurea-induced ATP-sensitive potassium channel closure. Molecular Pharmacology,1999,55:1060-1066.
  • 5O′Rourke B. Myocardial KATP channels in preconditioning. Circulation Research,2000,87:845-855.
  • 6Croop LC, Pelkonen R, Koskimies S, et al. Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes. Diabetes Care,1986,9:129-133.
  • 7Jonsson A, Hallengren B, Rydberg T, et al. Effects and serum levels of glibenclamide and its active metabolites in patients with type 2 diabetes. Diabetes, Obesity and Metabilism,2001,3:403-409.
  • 8RydbergT, Roder M, Jonsson A, et al. Hypoglycemic activity of glyburide(glibenclamide) metabolites in humans. Diabetes Care,1994,17:1026-1030.
  • 9Butler AE, Janson J, Bonner-Weir S, et al. β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes,2003,52:102-110.
  • 10Efanova IB, Zaitsev SV, Zhivotoveky B, et al. Glucose and tolbutamide induced apoptosis in pancreatic β-cells. J Biol Chem,1998,273:33501-33507.

共引文献65

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部